Key Stats
- Current Price: ~$354
- Q1 2026 Revenue: $111.7B (+2% YoY)
- Q1 2026 Adjusted EPS: $7.23
- Q1 2026 Medical Care Ratio: 83.9% (vs. 84.8% in Q1 2025)
- Updated Full-Year 2026 Adjusted EPS Guidance: Greater than $18.25
- Optum Health Q1 Adjusted Earnings: $1.3B
- Share Repurchase Plan: At least $2B by end of Q2 2026
- TIKR Model Price Target: $640
- Implied Upside: ~81%
UnitedHealth Group Q1 2026 Earnings Breakdown
UnitedHealth Group stock (UNH) reported Q1 2026 adjusted earnings per share of $7.23, well ahead of internal expectations, alongside $111.7B in total revenue, reflecting 2% growth year-over-year.
The outperformance was driven by a combination of disciplined pricing, favorable reserve development, and a meaningful recovery at Optum Health, where adjusted earnings reached $1.3B for the quarter.
Optum Health’s $1.3B result came in ahead of the company’s own guidance midpoint of $1.575B annualized run rate and reflected two distinct tailwinds: favorable prior-period reserve development concentrated in markets where clinical management has improved, and a 12% year-over-year increase in patient-facing hours as operational execution tightened across nearly 70% of care settings.
The medical care ratio came in at 83.9%, improving from 84.8% in Q1 2025, according to Chief Financial Officer Wayne DeVeydt on the Q1 2026 earnings call.
DeVeydt attributed the improvement to pricing discipline, strong medical cost management, and favorable reserve development, including roughly $500M in net prior-year development for the quarter.
UnitedHealthcare’s Medicare and Retirement segment saw trend progression broadly in line with pricing assumptions, with Tim Noel, CEO of UnitedHealthcare, noting modest favorability in government programs while describing utilization as continuing at elevated levels consistent with 2025.
Community and State performance reflected ongoing Medicaid margin pressure, with the company reiterating expectations for negative Medicaid margins in 2026, and modest improvement beginning in 2027 as state rate processes catch up with elevated trend.
Total domestic membership declined to 49.1 million from 49.8 million at year-end 2025, consistent with the company’s stated strategy of prioritizing margin recovery over growth, particularly in Medicare Advantage and individual ACA, where membership is expected to fall by approximately one-third in 2026.
Management raised full-year 2026 adjusted EPS guidance to greater than $18.25, up from the prior floor, while describing an earnings cadence that is roughly two-thirds first-half weighted.
UnitedHealth Group stock’s board accelerated share repurchases earlier than originally planned, with DeVeydt confirming at least $2B to be deployed by end of Q2, citing the company’s view that shares are trading at a deep discount to intrinsic value.
The company also completed the sale of its U.K. business in Q1, generating a $525M gain, of which $400M was contributed to the United Health Foundation; these items were excluded from adjusted earnings.
UnitedHealth Group Stock: What the Financials Show
The Q4 2025 income statement shows a business whose operating margin has been under sustained pressure since mid-2025, with the Q1 2026 transcript suggesting early stabilization that the full financial picture has yet to reflect.
Total revenues reached $113.2B in Q4 2025, up ~12% year-over-year.
Q3 2025 revenue of $113.2B and Q2 2025 revenue of $111.6B show revenue momentum holding across the back half of 2025, but operating income collapsed from $9.1B in Q1 2025 to $5.2B in Q2 and $4.3B in Q3, before falling to $380M in Q4.
Operating margin compressed from 8.3% in Q1 2025 to 0.3% in Q4 2025, a deterioration of 8 percentage points across four quarters, driven by escalating policy benefits and SG&A costs.
SG&A expenses reached $17.0B in Q4 2025, up from $13.6B in Q1 2025, a significant step-up that reflected the $900M incentive compensation accrual discussed on the Q1 2026 call as well as restructuring actions taken in Q4.
Policy benefits reached $82.0B in Q4 2025, up from $73.4B in the year-ago quarter, consistent with the elevated medical trend environment management has described as the central challenge heading into 2026.
What Does the Valuation Model Say?
The TIKR model prices UnitedHealth Group stock at $640, implying ~81% upside from the current price of ~$354, with a mid-case annualized return of ~13.5% through December 2030.
The model assumes a revenue CAGR of 5.6% in the mid case and a net income margin of 5.0%, both conservative relative to UNH’s 10-year historical revenue CAGR of 11% and net income margins that averaged above 6% before the 2024-2025 cost cycle inflection.
Q1 2026’s adjusted EPS of $7.23 and the raised full-year guidance of greater than $18.25 suggest the earnings recovery is ahead of where the market had priced UnitedHealth Group stock entering the year.
The investment case is incrementally stronger after this report, but execution risk in the second half remains material: the company’s own guidance flags that first-half earnings will represent roughly two-thirds of the full year, meaning the back half must hold to validate the recovery thesis.
The central tension: UNH’s Q1 recovery was real and ahead of plan, but more than half of the bull case depends on margin trends that management has explicitly said will deteriorate from Q1 levels before improving.
What Has to Go Right
- Medical care ratio improvement must be durable: the 83.9% Q1 MCR was supported by favorable reserve development and lower-than-expected respiratory activity, which management expects to moderate in Q2.
- Optum Health must sustain its operational gains: the $1.3B Q1 result was driven partly by prior-period development, but also by a 12% increase in patient-facing hours and a ~35% reduction in skilled nursing admissions in key markets, which need to hold as the program scales nationally.
- Medicaid rate adjustments must materialize: the company expects negative Medicaid margins through 2026, with modest improvement beginning in 2027; state rate processes still open for the remainder of 2026 represent a binary event for the earnings recovery path.
- Medicare Advantage pricing must hold: management priced 2026 MA trend at ~10%, above the 7-8% historical run rate; if trend stays at elevated levels without acceleration, pricing discipline should translate to the 50 basis point year-over-year margin improvement management has guided.
What Could Still Go Wrong
- Q2 MCR seasonality is a known headwind: management guided first-half MCR at more than 250 basis points below the full-year midpoint, which means Q2 and H2 will carry a proportionally heavier cost burden.
- The $900M Q1 incentive compensation accrual compresses comparability: only $35M of incentive compensation was recognized in Q1 2025, making UnitedHealth Group stock’s year-over-year segment results difficult to interpret cleanly.
- ACA membership contraction is accelerating: with individual ACA membership expected to fall by approximately one-third in 2026, premium revenue in that segment is actively shrinking while per-member complexity could rise.
- The PDR liability at Optum Health remains above $600M for the full year, reflecting contracts still under negotiation that could result in de-delegation or exit if pricing alignment is not achieved.
Should You Invest in UnitedHealth Group Incorporated?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UNH stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UnitedHealth Group Incorporated alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze UNH stock on TIKR for Free →
